Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cellectar Biosciences Sees Preliminary Q3 2023 Cash And Cash Equivalents $19M Down From $19.9M YoY; R&D Exepsne $7.3M Up From $5.4M YoY; G&A Expense $2.1M Down From $2.4M YoY

Author: Benzinga Newsdesk | November 02, 2023 08:14am

Posted In: CLRB